MedTrace Logo

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

NCT01521494 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2018-08-23

Study results available
· View outcomes & findings →

Summary

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

Conditions

  • Chronic Kidney Disease Requiring Hemodialysis

Interventions

DRUG

PA21

DRUG

PA21

DRUG

PA21

DRUG

PA21

DRUG

Placebo

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tatsuro Takei · Clinical Development Department, Kissei pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-11
Primary Completion
2012-07-03
Completion
2012-07-03

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521494 on ClinicalTrials.gov